Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2086389

COC(=O)c1ccc(CN)nc1.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
KDM4E B2RXH2 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
LOXL2 Q9Y4K0 2/20 0.46
GABRA5 P31644 2/20 0.41
MAPT P10636 3/20 0.41
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
NOTUM Q6P988 2/20 0.40
ALDH1A1 P00352 1/20 0.39
F11 P03951 1/20 0.38
KLKB1 P03952 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880698 0.90 MAPK1 (0.59) MAPK1KDM4EL3MBTL1LOXL2MAPT
Hydrochloric Acid SCHEMBL366796 0.88 MAPK1 (0.57) MAPK1KDM4EL3MBTL1LOXL2MAPT
Hydrochloric Acid SCHEMBL6878590 0.88 MAPK1 (0.57) MAPK1KDM4EL3MBTL1LOXL2MAPT
Trifluoroacetic Acid SCHEMBL2081865 0.84 L3MBTL1 (0.49) L3MBTL1LOXL2GABRA5MAPTALDH1A1
SCHEMBL2081869 0.80 MAPT (0.38) MAPK1KDM4EL3MBTL1LOXL2GABRA5
Trifluoroacetic Acid SCHEMBL6949653 0.79 F11 (0.44) MAPK1KDM4EL3MBTL1RAB9ANPC1
SCHEMBL6205940 0.78 MAPK1 (0.56) MAPK1KDM4EL3MBTL1LOXL2MAPT
Trifluoroacetic Acid SCHEMBL28281967 0.78 LOXL2 (0.77) MAPK1LOXL2MAPTKMT2APOLB
SCHEMBL17298235 0.77 MAPK1 (0.59) MAPK1KDM4EL3MBTL1LOXL2MAPT
SCHEMBL2717504 0.77 MAPK1 (0.51) MAPK1KDM4EL3MBTL1GABRA5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863269-B2 protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants SANOFI-AVENTIS (FR) 2011-01-04 US disclosed
EP-2054412-B1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI AVENTIS (FR) 2009-12-02 EP disclosed
US-20090192150-A1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2009-07-30 US disclosed
EP-2054412-A2 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY Sanofi-Aventis (FR) 2009-05-06 EP disclosed
WO-2008014888-A2 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192150-A1 IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY F2R, TFPI, F2RL1 MAPK1 330/4885KDM4E 4314/4885L3MBTL1 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.